China/Germany: Biotech Chinese Investor Takes Over German Biotech Start-Up Gilupi

Editor: Dominik Stephan

Viroad, a Chinese biotech investment company, plans to acquire Gilupi, a German start-up company specialized in cancer diagnostics. Viroad is already the largest investor in the Potsdam-based bio-firm.

Related Vendors

(Bild: Ernhofer/PROCESS)

Potsdam/Germany – Gilupi now hopes to be able to continue the development of its product portfolio as well as have an easier access to the Chinese market., where the company has filed a cell collector technology for approval.

The managing director at GILUPI, Dr. Jens Pfannkuche, is convinced that the company can market its promising technology and other diagnostic products, especially in Europe and Asia now: "Predictive and companion diagnostics are more and more important in the oncological area, since there are various treatment options. Together with Viroad we can realize a rapid market access in China in addition to the core markets of Europe."

Xu Baozhi, general manager of the Chinese medical technology company Viroad, emphasizes "Gilupi products have met the strong demand in our Chinese market. The population in our country is aging, and the market for diagnostics is growing dynamically. We are therefore looking forward to expand with our German partner."